<DOC>
	<DOCNO>NCT02685826</DOCNO>
	<brief_summary>This multicenter , open-label , Phase 1/2 study determine recommend dose regimen durvalumab combination lenalidomide ( LEN ) without dexamethasone ( dex ) subject Newly diagnose multiple myeloma ( NDMM ) . The study consist dose-finding phase well parallel dose-expansion phase determine optimal regimen .</brief_summary>
	<brief_title>A Study Durvalumab Combination With Lenalidomide With Without Dexamethasone Subjects With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description>The dose-finding phase determine recommend dose ( RD ) durvalumab combination lenalidomide ( LEN ) without dexamethasone ( dex ) 28-day treatment cycle . Three treatment Cohorts ( A , B , C ) enrol parallel : - Cohort A : durvalumab + LEN +dex high risk Transplant non-eligible ( TNE ) Newly diagnose multiple myeloma ( NDMM ) subject ; - Cohort B : durvalumab + LEN +dex ( Dex 12 cycle ) ≥ 65 year old TNE NDMM subject high risk ; - Cohort C : durvalumab + LEN maintenance post-transplant high risk NDMM subject ; Based experience durvalumab indication , initial dose durvalumab 1500 mg treatment cohort . The dose durvalumab might de-escalate 750 mg level . The dose LEN 25 mg ( adjustable per CrCl ) value Days 1 21 28-day treatment cycle subject Cohort A B . The dose LEN 10 mg Days 1 21 28-day treatment cycle subject Cohort C. The dose dex 40 mg/day ( subject ≤ 75 year old ) 20 mg/day ( subject &gt; 75 year old ) Days 1 , 8 , 15 , 22 28-day cycle Cohort A Cohort B ( 12 cycle ) . Initially , 6 subject enrol cohort receive 1500 mg durvalumab . The dose-limiting toxicity ( DLT ) evaluation period first treatment cycle . - If ≤ 1 6 initial subject experience DLT within first cycle , doseexpansion phase may initiate durvalumab 1500 mg recommend dose ( RD ) ; - If 2 6 initial subject experience DLT within first cycle , maximum tolerate dose ( MTD ) exceed de-escalation durvalumab 750 mg level review safety PK/Pd initial 6 subject DRT Any cohort may remove study base emerge PK , Pd , efficacy safety data . Dose de-escalation occur review safety ( DLT ) possibly PK/Pd data Dose Review Team ( DRT ) . Note : In US , two treatment arm ( A B ) enrol parallel . Cohort C enroll upon completion least 4 cycle follow-up safety assessment Cohorts A B .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subjects must satisfy follow criterion enrol study : 1 . Subject ≥ 18 year age time sign informed consent form ( ICF ) 2 . Subject must understand voluntarily sign ICF prior studyrelated assessments/procedures conduct 3 . Subject willing able adhere study visit schedule protocol requirement 4 . Subject must document diagnosis previously untreated ( cohort C , induction consolidation treatment along first Autologous stem cell transplantation ( ASCT ) allow ) , symptomatic Multiple Myeloma ( MM ) define criterion : MM diagnostic criterion ( 3 require ) ; Monoclonal protein present serum and/or urine Clonal bone marrow plasma cell ≥10 % biopsyproven bony extramedullary plasmacytoma Any one follow myeloma define event : one follow Myelomarelated organ dysfunction ( least one follow ) ; ( C ) Calcium elevation ( serum calcium &gt; 11.5 mg/dl ) ( &gt; 2.65 mmol/L ) ( R ) Renal insufficiency ( serum creatinine &gt; 2 mg/dl ) ( 177 µmol/L ) creatinine clearance &lt; 40 ml/min ( A ) Anemia ( hemoglobin &lt; 10 g/dl &gt; 2 g /dL low limit laboratory normal ) ( B ) Bone lesion ( lytic osteopenic ) one bone lesion skeletal radiography , Computed tomography ( CT ) , PETCT one follow biomarkers malignancy : Clonal bone marrow plasma cell percentage* ≥60 % Abnormal serum free lightchain ratio ≥100 ( involve kappa ) &lt; 0.01 ( involve lambda ) &gt; 1 focal lesion detect functional imaging include PET/CT and/or whole body magnetic resonance imaging ( MRI ) AND measurable disease protein electrophoresis analysis define follow : IgG MM : Serum monoclonal paraprotein ( Mprotein ) level ≥ 1.0 g/dl urine Mprotein level ≥ 200 mg/24 hour IgA MM : Serum Mprotein level ≥ 0.5 g/dl urine Mprotein level ≥ 200 mg/24 hour IgM MM ( IgM Mprotein plus lytic bone disease document skeletal survey plain film ) : Serum Mprotein level ≥ 1.0 g/dl urine Mprotein level ≥ 200 mg/24 hour IgD MM : Serum Mprotein level ≥ 0.05 g/dl urine Mprotein level ≥ 200 mg/24 hour Light chain MM : Serum Mprotein level ≥ 1.0 g/dl urine Mprotein level ≥ 200 mg/24 hour 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 6 . Females childbearing potential ( FCBP1 ) must : 1 . Have two negative pregnancy test verify investigator prior start study treatment . She must agree ongoing pregnancy test course study , end study treatment . This apply even subject practice true abstinence2 heterosexual contact . 2 . She must either commit true abstinence heterosexual contact ( must review monthly basis source document ) agree use , able comply , effective contraception without interruption , 28 day prior start study treatment , study therapy ( include dose interruption ) , 90 day discontinuation study treatment . 3 . Refrain egg cell blood donation 90 day final dose durvalumab . 7 . Male subject must : 1 . Practice true abstinence2 ( must review monthly basis ) agree use condom sexual contact pregnant female FCBP participate study , dose interruption least 90 day follow study treatment discontinuation , even undergone successful vasectomy . 2 . Refrain sperm blood donation least 90 day final dose durvalumab 8 . For Cohort A subject must transplant noneligible ( TNE ) meet least one follow high risk factor : 1 . Cytogenetic abnormality find malignant myeloma clone ( 4 ; 14 ) ; / del ( 17p ) ; / 1q rearrangement ; / ( 14:16 ) ; 2 . ISS Stage III ; 3 . Serum LDH &gt; 2 x ULN ( Upper limit normal ) ; 9 . For Cohort B subject must ≥ 65 year age time sign informed consent form ( ICF ) transplant noneligible ( TNE ) ; exclude subject meet Cohort A criterion 10 . For Cohort C subject must first autologous stem cell transplantation ( ASCT ) NDMM meet follow criterion : 1 . Have posttransplant response Partial response ( PR ) good time enrollment study ; 2 . Have one follow high risk factor time NDMM diagnosis ; Cytogenetic abnormality find malignant myeloma clone ( 4 ; 14 ) ; / del ( 17p ) ; / 1q rearrangement ; / ( 14 ; 16 ) ; ISS stage III ; Serum LDH &gt; 2 x ULN ; c. Minimal residual disease ( MRD ) positive ( defined 1 malignant cell 105 cell ) measure ClonoSIGHT NGS assay BMA sample ) time enrollment study ; BMA sample collect time multiple myeloma diagnosis , prior induction therapy available central MRD assessment ClonoSIGHT NGS assay The presence follow exclude subject enrollment : 1 . Previous treatment antimyeloma therapy ( include radiotherapy , bisphosphonates , single short course steroid ( ie , less equal equivalent dexamethasone 40 mg/day 4 day ; short course steroid treatment must give within 14 day Cycle 1 Day 1 ) , Cohort C , induction consolidation treatment along first Autologous stem cell transplantation ( ASCT ) allow ) 2 . Any following laboratory abnormality : 1 . Absolute neutrophil count ( ANC ) &lt; 1,000/μL 2 . Untransfused platelet count &lt; 75,000 cells/μL 3 . Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( SGOT/AST ) alanine aminotransferase ( SGPT/ALT ) &gt; 2.5 × upper limit normal ( ULN ) 4 . Serum total bilirubin &gt; 1.5 × ULN &gt; 3.0 mg/dL subject document Gilbert 's syndrome 5 . Corrected serum calcium &gt; 13.5 mg/dL ( &gt; 3.4 mmol/L ) 3 . Renal failure require hemodialysis peritoneal dialysis 4 . Any serious medical condition place subject unacceptable risk participates study . Examples medical condition , limited , subject unstable cardiac disease define : cardiac event myocardial infarction ( MI ) within past 6 month , NYHA ( New York Heart Association ) heart failure class IIIIV , uncontrolled atrial fibrillation hypertension ; subject condition require chronic steroid immunosuppressive treatment , rheumatoid arthritis , multiple sclerosis lupus , likely need additional steroid immunosuppressive treatment addition study treatment 5 . Peripheral neuropathy ≥ Grade 2 6 . Primary AL ( immunoglobulin lightchain ) amyloidosis myeloma complicate amyloidosis 7 . Prior history malignancy , MM , unless subject free disease ≥ 5 year exception follow noninvasive malignancy : 1 . Basal cell carcinoma skin 2 . Squamous cell carcinoma skin 3 . Carcinoma situ cervix 4 . Carcinoma situ breast 5 . Incidental histologic find prostate cancer ( T1a T1b use TNM [ tumor , node , metastasis ] clinical staging system ) prostate cancer curative 8 . Subjects positive human immunodeficiency virus ( HIV ) ; chronic active hepatitis B active hepatitis A , C 9 . Subject prior exposure immunotherapy , include , limited , anti CTLA4 , antiPD1 , antiPDL1 monoclonal antibody inhibitor , cellbased therapy , cancer vaccine 10 . Subjects history organ allogeneic stem cell transplantation 11 . Subjects clinical evidence central nervous system ( CNS ) pulmonary leukostasis , disseminate intravascular coagulation , CNS multiple myeloma , plasma cell leukemia 12 . Known suspected hypersensitivity excipients contain formulation durvalumab , lenalidomide , dexamethasone 13 . Major surgery ( define investigator ) within 28 day prior first dose study treatment 14 . Received prior treatment ( reason ) monoclonal antibody within 5 halflives initiate study treatment 15 . Use investigational agent within 28 day 5 halflives ( whichever longer ) initiate study treatment 16 . Current prior use immunosuppressive medication within 14 day prior first dose study treatment . The following exception criterion : 1 . Intranasal , inhale , topical local steroid injection ( eg , intraarticular injection ) ; 2 . Systemic corticosteroid physiologic dos exceed 10 mg/day prednisone equivalent ; 3 . Steroids premedication hypersensitivity reaction ( eg , compute tomography ( CT ) scan premedication ) ; 17 . Active prior document autoimmune inflammatory disorder ( include inflammatory bowel disease ( eg , colitis , Crohn 's disease ] , diverticulitis exception prior episode resolve diverticulosis , celiac disease , irritable bowel disease , serious gastrointestinal chronic condition associate diarrhea ; systemic lupus erythematosus ; Wegener 's syndrome [ granulomatosis polyangiitis ) ; myasthenia gravis ; Graves ' disease ; rheumatoid arthritis ; hypophysitis , uveitis ) within past 3 year prior start treatment . The following exception criterion : 1 . Subjects vitiligo alopecia ; 2 . Subjects hypothyroidism ( eg , follow Hashimoto syndrome ) stable hormone replacement ; 3 . Subjects psoriasis require systemic treatment ; 18 . History primary immunodeficiency 19 . Subject incidence gastrointestinal disease may significantly alter absorption LEN 20 . Receipt live , attenuated vaccine within 30 day prior first dose durvalumab 21 . Unable unwilling undergo protocol require thromboembolism prophylaxis ( Cohort C , subject history VTE ) 22 . Females pregnant , nurse breastfeeding , intend become pregnant participation study 23 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study 24 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study 25 . Any condition confound ability interpret data study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Open-label</keyword>
	<keyword>Phase 1/2</keyword>
	<keyword>Durvalumab</keyword>
	<keyword>MEDI4736</keyword>
	<keyword>Lenalidomide ( Len )</keyword>
	<keyword>Dexamethasone ( dex )</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Newly-Diagnosed ( NDMM )</keyword>
	<keyword>Transplant Non-eligible ( TNE )</keyword>
	<keyword>PD-L1</keyword>
</DOC>